ProCE Banner Activity

plasmaMATCH Cohort B: Neratinib ± Fulvestrant for Patients With HER2 Mutation–Positive Advanced Breast Cancer as Identified by ctDNA Analysis

Slideset Download
Conference Coverage
Neratinib with or without fulvestrant was well tolerated and active in patients with advanced breast cancer and HER2 mutations identified by ctDNA testing.

Released: December 17, 2019

Expiration: December 15, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen